Intralesional injections of Citoprot‐P(®) (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation

To investigate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers (DFU) A double‐blind trial was carried out to test two rhEGF dose levels in type 1 or 2 diabetes patients with Wagner’s grade 3 or 4 ulcers, with high risk of amputation. Subj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int Wound J
Main Authors: Fernández‐Montequín, José I, Infante‐Cristiá, Ena, Valenzuela‐Silva, Carmen, Franco‐Pérez, Neobalis, Savigne‐Gutierrez, William, Artaza‐Sanz, Heriberto, Morejón‐Vega, Lourdes, González‐Benavides, Cecilio, Eliseo‐Musenden, Osvaldo, García‐Iglesias, Elizeth, Berlanga‐Acosta, Jorge, Silva‐Rodríguez, Ricardo, Betancourt, Blas Y, López‐Saura, Pedro A
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2007
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951380/
https://ncbi.nlm.nih.gov/pubmed/17953679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1742-481X.2007.00344.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados